| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Aug'13 | Dec'12 | Aug'12 |
|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||
Net loss | |||||||||
-12,775 | -7,300 | -3,595 | -54,206 | -12,507 | -14,307 | -8,579 | -89 | - | -89 |
Net loss | |||||||||
- | - | - | - | - | - | - | - | -6,328 | - |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Acquired in-process research and development | |||||||||
3,031 | 0 | - | - | - | - | - | - | - | - |
Goodwill impairment (Note 6) | |||||||||
3,283 | 0 | - | - | - | - | - | - | - | - |
In-process research and development expense | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
In-process research and development expense | |||||||||
- | - | - | 39,500 | 0 | - | - | - | - | - |
Depreciation | |||||||||
4 | 15 | 23 | 36 | 56 | - | - | - | 104 | - |
Amortization of right of use asset | |||||||||
23 | 0 | - | - | - | - | - | - | - | - |
Gain on sale of property and equipment | |||||||||
2 | 15 | 0 | - | - | - | - | - | - | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | 88 | - | - | - | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | - | 52 | - | - | - |
Amortization of hybrid debt instrument discount | |||||||||
- | - | - | 544 | 108 | 0 | - | - | - | - |
Non-cash interest expense | |||||||||
- | - | - | - | 153 | - | - | - | - | - |
Non-cash interest expense | |||||||||
- | - | - | 174 | - | 0 | 0 | - | 51 | - |
Share-based expense | |||||||||
806 | 1,362 | 1,784 | 1,922 | 2,201 | 1,513 | 431 | - | 339 | - |
Warrant-based income (expense) for services | |||||||||
- | - | -126 | 1,121 | - | - | - | - | - | - |
Warrant expense for services | |||||||||
- | - | - | - | 933 | 239 | - | - | - | - |
Vendor share-based expense | |||||||||
47 | 69 | 135 | 180 | - | - | - | - | - | - |
Vendor share-based payments | |||||||||
47 | 69 | 135 | 180 | 392 | - | - | - | - | - |
Issuance of warrants in connection with reverse stock split | |||||||||
63 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of derivative liability | |||||||||
- | - | - | 2,125 | -2,125 | 0 | - | - | - | - |
Loss on issuance of hybrid debt instrument | |||||||||
- | - | - | - | 59 | 0 | - | - | - | - |
Loss on issuance of hybrid debt instrument | |||||||||
- | - | - | -1,690 | - | - | - | - | - | - |
Hybrid debt instrument issuance costs | |||||||||
- | - | - | 12 | 30 | 0 | - | - | - | - |
Loss on conversion of debt | |||||||||
- | - | - | -6,394 | 0 | - | - | - | - | - |
Settlement of accounts payable with common stock | |||||||||
- | - | - | 243 | 0 | - | - | - | - | - |
Loss on disposal of subsidiaries | |||||||||
- | - | - | - | - | -1,069 | 0 | - | - | - |
Fee paid on disposal of subsidiaries | |||||||||
- | - | - | - | - | 430 | 0 | - | - | - |
Non-cash issuance of warrants | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
Foreign currency translation | |||||||||
- | - | - | - | -369 | 353 | 14 | - | 42 | - |
Other non-cash transactions | |||||||||
- | - | - | - | 127 | 0 | - | - | - | - |
Non-cash impairment of acquired In-Process Research and Development | |||||||||
- | - | - | - | - | - | - | - | 1,087 | - |
Other non-cash transactions | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | - | - | 38 | - | 19 |
(Gain) loss on settlement | |||||||||
- | - | - | - | - | - | - | 10 | - | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable | |||||||||
- | - | -3,000 | 3,000 | 0 | - | - | 77 | - | -99 |
Prepaid expenses and other assets | |||||||||
653 | 251 | -280 | 234 | -21 | 24 | 7 | - | 31 | - |
Accounts payable, accrued expenses and other liabilities | |||||||||
-227 | -343 | -8 | -1,018 | 943 | -479 | 2,066 | - | -1,443 | - |
Net cash used in operating activities | |||||||||
- | - | - | - | -5,300 | -12,683 | -6,052 | - | - | - |
Prepaid expenses | |||||||||
- | - | - | - | - | - | - | -9 | - | 0 |
Accounts payable | |||||||||
- | - | - | - | - | - | - | 239 | - | 183 |
Accrued interest | |||||||||
- | - | - | - | - | - | - | 12 | - | 13 |
Net cash used in operating activities | |||||||||
-6,399 | -6,463 | 1,494 | -8,787 | - | - | - | 280 | -6,262 | -12 |
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||
Purchases of property and equipment | |||||||||
- | - | 9 | 16 | 1 | 57 | 78 | - | 130 | - |
Proceeds from sale of property and equipment | |||||||||
2 | 22 | 0 | - | 7 | 5 | 0 | - | 37 | - |
Cash acquired from acquisition | |||||||||
- | - | - | - | - | 43 | 0 | - | -0 | - |
Cash transferred in connection with Hive Out Agreement | |||||||||
- | - | - | - | - | 43 | 0 | - | - | - |
Change in restricted cash | |||||||||
- | - | - | - | - | - | 66 | - | - | - |
Net cash used in investing activities | |||||||||
- | - | - | - | 6 | -52 | -144 | - | - | - |
Amortizable overhaul of aircraft | |||||||||
- | - | - | - | - | - | - | -259 | - | 0 |
Net cash provided by investing activities | |||||||||
2 | 22 | -9 | -16 | - | - | - | -259 | -92 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||
Proceeds from issuance of debt | |||||||||
- | - | - | 4,500 | 3,100 | 0 | - | - | - | - |
Payments on debt | |||||||||
- | - | - | 369 | 100 | 0 | - | - | - | - |
Proceeds from issuance of units in offering | |||||||||
- | - | - | 8,969 | 0 | - | - | - | - | - |
Proceeds from issuance of promissory note | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
Proceeds from issuance of common stock | |||||||||
- | - | - | - | - | 10,000 | 0 | 0 | 421 | 35 |
Proceeds from exercise of stock options | |||||||||
- | - | - | - | - | 101 | 2 | - | 0 | - |
Employee participation in JSOP | |||||||||
- | - | - | - | - | - | - | - | 61 | - |
Stock issuance costs | |||||||||
- | - | - | - | - | - | - | - | 80 | - |
Payments on loan from related party | |||||||||
- | - | - | 380 | 0 | 286 | 0 | - | 706 | - |
Net cash provided by financing activities | |||||||||
- | - | - | - | 3,000 | 9,815 | 2 | - | - | - |
Net proceeds from issuance of common stock and warrants | |||||||||
13,421 | 0 | - | - | - | - | - | - | - | - |
Net proceeds from issuance of common stock and warrants in registered direct offering | |||||||||
2,699 | 0 | - | - | - | - | - | - | - | - |
Proceeds from exercise of warrants | |||||||||
6 | 1,480 | 0 | - | - | - | - | - | - | - |
Net cash provided by financing activities | |||||||||
16,127 | 1,480 | 0 | 12,719 | - | - | - | 0 | -303 | 35 |
Net change in cash and restricted cash | |||||||||
9,729 | -4,961 | 1,484 | - | - | - | - | - | - | - |
Effect of exchange rate change on cash | |||||||||
- | - | - | - | -80 | 587 | -102 | - | 677 | - |
Net change in cash, excluding restricted cash | |||||||||
- | - | - | 3,915 | -2,375 | -2,332 | -6,297 | 21 | -5,980 | 22 |
Cash paid for interest | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |
SUPPLEMENTAL CASH FLOW INFORMATION: | |||||||||
Cash paid for interest | |||||||||
0 | 0 | 1 | 15 | 0 | 4 | 0 | - | - | - |
Cash paid for income taxes | |||||||||
- | - | - | - | - | - | 0 | - | - | - |
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | |||||||||
Right of use assets obtained in exchange for lease liability | |||||||||
43 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock to vendor | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock to acquire in-process research and development | |||||||||
3,031 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock to adjust for Reverse Stock Split | |||||||||
0 | 0 | - | - | - | - | - | - | - | - |
Issuance of common stock from cashless exercise of purchase warrants | |||||||||
2 | 0 | - | - | - | - | - | - | - | - |
Interest paid in common stock | |||||||||
- | - | - | 255 | - | - | - | - | - | - |
Purchase of XBIO IPR&D with common stock | |||||||||
- | - | - | 39,500 | 0 | - | - | - | - | - |
Issuance of note in settlement of deferred payroll costs | |||||||||
- | - | - | 369 | 0 | - | - | - | - | - |
Reclassification of related party loan principal to accounts payable | |||||||||
- | - | - | 14 | 0 | - | - | - | - | - |
Exchange of common stock for Series A preferred stock | |||||||||
- | - | - | 0 | 0 | - | - | - | - | - |
Conversion of Series B preferred stock to common stock | |||||||||
0 | 0 | 0 | 0 | 0 | - | - | - | - | - |
Issuance of common stock in connection with pending asset acquisition | |||||||||
- | - | - | - | 3,744 | 0 | - | - | - | - |
Convertible debt paid in common stock | |||||||||
- | - | - | 7,000 | 0 | - | - | - | - | - |
Interest paid in common stock | |||||||||
- | - | - | - | 75 | 0 | - | - | - | - |
Convertible debt paid in public offering units | |||||||||
- | - | - | 500 | 0 | - | - | - | - | - |
Issuance of warrants in connection with debt | |||||||||
- | - | - | 2,107 | 1,626 | 0 | - | - | - | - |
Recording of derivative liability in connection with debt | |||||||||
- | - | - | 4,120 | 1,419 | 0 | - | - | - | - |
Reclassification of common shares issuable to accounts payable | |||||||||
- | - | 65 | 0 | - | - | - | - | - | - |
Issuance of common stock for promissory note converted in 2016 | |||||||||
- | - | 0 | 0 | - | - | - | - | - | - |
Equity consideration transferred in the acquisition | |||||||||
- | - | - | - | - | 3,750 | 0 | - | - | - |
Repurchase and cancellation of common stock in disposal of subsidiaries | |||||||||
- | - | - | - | - | 3,750 | 0 | - | - | - |
Issuance of common stock in connection with SymbioTec GmbH acquisition | |||||||||
- | - | - | - | - | - | - | - | 9,339 | - |
Loan to JSOP trustees | |||||||||
- | - | - | - | - | - | - | - | -4,692 | - |
Cash paid for taxes | |||||||||
- | - | - | - | - | - | - | 0 | - | 0 |